| Literature DB >> 23840204 |
Véronique Brulotte1, François A Leblond, Stéphane Elkouri, Eric Thérasse, Vincent Pichette, Pierre Beaulieu.
Abstract
Purpose. Contrast-induced nephropathy (CIN) can contribute to acute kidney injury (AKI) in patients undergoing endovascular aortic aneurysm surgery. We evaluated the incidence of AKI together with the evolution of early biomarkers of renal injury in patients receiving bicarbonates or NaCl 0.9%. Methods. This study involved endovascular aortic aneurysm surgery patients. Group A (n = 17) received bicarbonates 3 mL/kg/h for 1 h before the procedure and then 1 mL/kg/h until 6 h after surgery, whereas group B (n = 17) received NaCl 0.9% using the same protocol. Biomarkers of renal injury from urine (interleukin-18 (IL-18), neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-β-D-glucosaminidase (NAG), and kidney injury molecule 1 (KIM-1)) and blood (NGAL, cystatin C) were measured at baseline and 3, 24, and 48 h postoperatively. Results. AKI occurred in 1 patient (2.9%), in the bicarbonates group. IL-18, NAG, NGAL, and KIM-1 significantly rose in both groups after the surgery. There was a greater rise in NGAL and IL-18 after 3 h in the bicarbonates versus NaCl 0.9% group: 1115% versus 240% increase (P = 0.03) and 338% increase versus 1.4% decrease (P = 0.01). Conclusions. Despite significant elevation in biomarkers of renal injury, we demonstrated a low rate of AKI following endovascular aortic surgery.Entities:
Year: 2013 PMID: 23840204 PMCID: PMC3694372 DOI: 10.1155/2013/467326
Source DB: PubMed Journal: Anesthesiol Res Pract ISSN: 1687-6962
Figure 1Demographic subject characteristics.
| Sodium bicarbonate | Sodium chloride | |
|---|---|---|
| Age (yr) | 71.9 (6.1) | 75.6 (6.0) |
| Sex (male) | 14/17 | 14/17 |
| Weight (kg) | 80.5 (14.2) | 80.6 (12.1) |
| Aneurysm | ||
| Thoracic | 0/17 | 1/17 |
| Infrarenal | 17/17 | 16/17 |
| CIN risk scorea | 4.5 (3.8) | 5.8 (4.1) |
| Diabetes | 2/17 (12) | 2/17 (12) |
| Intraoperative hypotension | 3/17 (18) | 3/17 (18) |
| CHFb | 1/17 (6) | 0/17 |
| Age >75 | 6/17 (35) | 9/17 (53) |
| Anemia | 4/17 (24) | 4/17 (24) |
| Chronic renal failure | 0/17 | 4/17 (24) |
| Contrast volume (mL) | 140.1 (70.7) | 159.5 (50.7) |
| Baseline creatinine( | 82.1 (14.5) | 96.5 (41.8) |
| Medicationc | ||
| ACE inhibitors | 6/17 (35) | 5/17 (29) |
| Aminoglycosides | 0/17 | 0/17 |
| Diuretics | 3/17 (17) | 4/17 (24) |
| Vancomycinb | 4/17 (24) | 4/17 (24) |
| Durationd (min)† | 105.0 (30) | 117.0 (31) |
| Days to discharge† | 2.0 (1) | 2.0 (1) |
| Perioperative fluids | ||
| Ringer lactate (mL) | 1767.6 (544.6) | 1561.8 (536.1) |
Values are reported as means (standard deviation) and as proportions (%).
†Values expressed as median (interquartile range).
ACE: angiotensin-converting enzyme; CHF: congestive heart failure; CIN: contrast-induced nephropathy; IABP: intra-aortic balloon pump.
aAs defined by Mehran et al. [41]. See Appendix 1 for details; bdefined by a NYHA class > III/IV and/or history of pulmonary edema; creceived on the day of surgery; dduration from skin incision to complete wound closure.
Baseline values for creatinine, cystatin C, serum, and urinary NGAL, IL-18, NAG, and KIM-1 according to study group.
| Bicarbonates | Sodium chloride | |
|---|---|---|
| Serum | ||
| Creatinine ( | 82.1 (14.5) | 96.5 (41.8) |
| Cystatin C (ng/mL)† | 886.80 (172.1) | 866.10 (383.40) |
| NGAL (ng/ml) | 112.02 (36.67) | 110.99 (46.86) |
| Urinary | ||
| NGAL (ng/ | 0.90 (3.10) | 1.80 (2.75) |
| IL-18 (pg/ | 8.45 (5.60) | 10.67 (7.97) |
| NAG (IU/mmol creatinine)† | 0.60 (1.19) | 0.54 (2.0) |
| KIM-1 (ng/ | 0.175 (0.132) | 0.186 (0.145) |
Values are expressed as means (standard deviation).
†Values expressed as median (interquartile range).
IL-18: interleukin-18; KIM-1: kidney injury molecule-1; NAG: N-acetyl-β-D-glucosaminidase; NGAL: neutrophil gelatinase-associated lipocalin.
Mean difference from baseline of various biomarkers before and after (3, 24, and 48 hours) surgery, regardless of study group.
| Mean difference from baseline (%) | 95% CI for difference |
| |
|---|---|---|---|
| Serum | |||
| NGAL | |||
| Δ3 h | 3.2 | −6.4 to 12.8 | 0.51 |
| Δ24 h | 12.1 | −0.6 to 24.8 | 0.06 |
| Δ48 h | 18.9 | −10.4 to 48.1 | 0.19 |
| cysC | |||
| Δ3 h | −6.5 | −15.1 to 2.0 | 0.13 |
| Δ24 h | 2.0 | −6.2 to 10.2 | 0.62 |
| Δ48 h | 10.9 | −6.9 to 28.7 | 0.22 |
| Creatinine | |||
| Δ3 h | −22.8 | −26.6 to −18.9 | <0.001 |
| Δ24 h | −12.9 | −18.7 to −7.1 | <0.001 |
| Δ48 h | −9.7 | −17.0 to −2.4 | 0.01 |
|
| |||
| Urinary | |||
| IL-18 | |||
| Δ3 h | 145.7 | −116.5 to 407.8 | 0.27 |
| Δ24 h | 328.9 | 95.3 to 562.6 | 0.01 |
| Δ48 h | 410.2 | 126.5 to 693.8 | 0.01 |
| NAG | |||
| Δ3 h | 1294.0 | 422.6 to 2165.5 | 0.01 |
| Δ24 h | 775.9 | 328.6 to 1223.2 | <0.001 |
| Δ48 h | 1306.4 | 550.3 to 2062.6 | <0.001 |
| NGAL | |||
| Δ3 h | 619.3 | −123.0 to 1361.5 | 0.10 |
| Δ24 h | 647.5 | 94.6 to 1200.4 | 0.02 |
| Δ48 h | 1641.7 | −430.4 to 3713.7 | 0.11 |
| KIM-1 | |||
| Δ3 h | 20.8 | 3.2 to 38.3 | 0.02 |
| Δ24 h | 168.6 | 103.1 to 234.1 | <0.001 |
| Δ48 h | 246.4 | 149.6 to 343.2 | <0.001 |
Values expressed as mean percent change. CI: confidence interval.
cysC: cystatin C; IL-18: interleukin 18; KIM-1: kidney injury molecule 1; NAG: N-acetyl-β-D-glucosaminidase; NGAL: neutrophil gelatinase-associated lipocalin.
Baseline characteristics between the patient who developed AKI versus the patients who did not.
| AKI | No AKI | |
|---|---|---|
| Contrast volume (mL) | 300 | 145.3 (56.2) |
| Crystalloids (mL) | 3000 | 1624.2 (495.8) |
| Colloids (mL) | 1000 | 75.8 (220.8) |
| Urinary pH at 3 h | 8.0 | 6.7 (0.74) |
| Surgery duration (min) | 390 | 117.6 (41.7) |
| Mehran risk score [ | 3 | 5.18 (3.9) |
Values expressed as mean (standard deviation).
AKI: acute kidney injury.
(a)
| Serum | Urinary | ||||||
|---|---|---|---|---|---|---|---|
| Creatinine | cysC | NGAL | IL-18 | NAG | NGAL | KIM-1 | |
| Baseline | |||||||
| AKI | 62 | 775.90 | 106.50 | 3.50 | 0.20 | 1.10 | 0.149 |
| No AKI | 90.1 | 830.47 | 111.61 | 9.92 | 1.38 | 6.49 | 0.182 |
Values expressed as means.
AKI: acute kidney injury; cysC: cystatin C; IL-18: interleukin 18; KIM-1: kidney injury molecule 1; NAG: N-acetyl-β-D-glucosaminidase; NGAL: neutrophil gelatinase-associated lipocalin.
(b)
| Serum | Urinary | ||||||
|---|---|---|---|---|---|---|---|
| Creatinine | cysC | NGAL | IL-18 | NAG | NGAL | KIM-1 | |
| Δ3 h (%) | |||||||
| AKI | 69.68 | 33.78 | 30.70 | 3854.28 | 11550.00 | 10700.00 | −34.23 |
| No AKI | −23.88 | −7.91 | 2.33 | 17.76 | 940.38 | 271.66 | 22.66 |
| Δ24 h (%) | |||||||
| AKI | 66.13 | 3.45 | 87.61 | 1217.14 | 2150.00 | 7818.18 | 161.74 |
| No AKI | −15.31 | 1.99 | 9.51 | 298.28 | 728.48 | 400.23 | 168.85 |
| Δ48 h (%) | |||||||
| AKI | 75.81 | 54.71 | 286.20 | 2282.86 | 3200.00 | 22281.82 | 296.64 |
| No AKI | −12.72 | 8.81 | 6.14 | 316.51 | 1211.74 | 658.79 | 243.75 |
Values expressed as mean percent change from baseline.
AKI: acute kidney injury; cysC: cystatin C; IL-18: interleukin 18; KIM-1: kidney injury molecule 1; NAG: N-acetyl-β-D-glucosaminidase; NGAL: neutrophil gelatinase-associated lipocalin.